EUVIMEDFaigh amach EUVIMED
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Topical tacrolimus orabase versus topical clobetasol propionate orabase in the treatment of symptomatic oral lichen planus: a pilot randomized study

F M M Schroeder, E S Pedraça, V M Palma, V C Carrard, M A T Martins, F L D M Maito, D Q M Lisbôa, Fernanda Visioli

Clinical Oral Investigations · 2024

DOI: 10.1007/s00784-024-05943-5 ↗

At a glance

Vergleichsstudie in Clinical Oral Investigations, 2024. Written by F M M Schroeder and 7 co-authors. Institution: Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil. Major MEDLINE topics: Administration, Topical, Clobetasol, Lichen Planus, Oral, Tacrolimus. Cited 3 times so far (Crossref); 49 references. Funded by: CAPES, FIPE.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

OBJECTIVES: This pilot study aimed to compare the efficacy of 0.1% tacrolimus and 0.05% clobetasol propionate in orabase for treating symptomatic oral lichen planus (OLP). MATERIALS AND METHODS: Pilot, randomized, and controlled study conducted on 21 patients with symptomatic OLP, selected according to the clinical and histopathological criteria of Cheng et al. 2016. Twelve patients received 0.1% tacrolimus, and nine received 0.05% clobetasol, both in orabase for 30 days with a two-month follow-up. The patients were examined for scores of signs (ODSS), symptoms (VAS), quality of life (OHIP-14), anxiety (Beck Anxiety Scale), and treatment satisfaction (Hedonic Scale). RESULTS: Both treatments were effective in reducing ODSS, VAS, and Beck Anxiety Scale scores and performed well on the hedonic scale, yet without statistical difference between them. However, at the 1-month follow-up, patients in group Clobetasol showed a greater percentage reduction in ODSS score compared to baseline by 50% (p = 0.02) and significantly lower average values (p = 0.03) than those in group Tacrolimus. Longitudinal intragroup analysis revealed significant improvements over time in both groups for ODSS, and only in the tacrolimus group for OHIP-14 and Beck scores. CONCLUSIONS: Both tested protocols were effective over a three-month follow-up. However, due to the lower cost of clobetasol propionate it can be considered the first-choice option. Tacrolimus in orabase formulation may be a promising alternative for refractory lesions that do not respond to topical steroids. CLINICAL RELEVANCE: Managing symptomatic OLP is challenging. Comparisons between tacrolimus and clobetasol propionate in orabase formulations have not yet been thoroughly explored.

Subjects

MeSH terms (MEDLINE)

Administration, TopicalClobetasolLichen Planus, OralTacrolimusAdultAgedFemaleHumansMaleMiddle AgedImmunosuppressive AgentsPilot ProjectsQuality of LifeTreatment OutcomeCarboxymethylcellulose Sodium

Author keywords

Clobetasol propianateOral lichen planusTacrolimusTreatment orabase

Substances

ClobetasolImmunosuppressive AgentsTacrolimusOrabaseCarboxymethylcellulose Sodium

Authors and institutions

  • Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil.
  • Experimental Center Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.
  • Oral Pathology Department, School of Health and Life Sciences, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, 90619-900, Brazil.
  • Compounding Pharmacy Firm, Dose Certa Farmácia de Manipulação, Porto Alegre, RS, 90640-001, Brazil.
  • Oral Medicine Department, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, 90035-003, Brazil. fernanda.visioli@ufrgs.br.
  • Experimental Center Research, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil. fernanda.visioli@ufrgs.br.

Funding

  • CAPES
  • FIPE

Cite

APA

Schroeder, F. M. M., Pedraça, E. S., Palma, V. M., Carrard, V. C., Martins, M. A. T., Maito, F. L. D. M., Lisbôa, D. Q. M., & Visioli, F. (2024). Topical tacrolimus orabase versus topical clobetasol propionate orabase in the treatment of symptomatic oral lichen planus: a pilot randomized study. Clinical Oral Investigations. https://doi.org/10.1007/s00784-024-05943-5

Vancouver

Schroeder FMM, Pedraça ES, Palma VM, Carrard VC, Martins MAT, Maito FLDM, et al. Topical tacrolimus orabase versus topical clobetasol propionate orabase in the treatment of symptomatic oral lichen planus: a pilot randomized study. Clinical Oral Investigations. 2024. doi:10.1007/s00784-024-05943-5

BibTeX
@article{Schroeder2024,
  author = {Schroeder, F M M and Pedraça, E S and Palma, V M and Carrard, V C and Martins, M A T and Maito, F L D M and Lisbôa, D Q M and Visioli, Fernanda},
  title = {Topical tacrolimus orabase versus topical clobetasol propionate orabase in the treatment of symptomatic oral lichen planus: a pilot randomized study},
  journal = {Clinical Oral Investigations},
  year = {2024},
  doi = {10.1007/s00784-024-05943-5}
}
Start for free →